Nocturnal Breathing and Sleep in Patients With Chronic Obstructive Pulmonary Disease Staying at Altitude
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Chronic Obstructive Pulmonary Disease
- Sponsor
- University of Zurich
- Enrollment
- 50
- Locations
- 1
- Primary Endpoint
- Change in mean nocturnal oxygen saturation from baseline measured at 490 m
- Status
- Completed
- Last Updated
- 10 years ago
Overview
Brief Summary
The purpose of this study is to evaluate whether nocturnal breathing and sleep of patients with chronic obstructive pulmonary disease (COPD) are disturbed during a stay at moderate altitude.
Detailed Description
This randomized cross-over trial evaluates the hypothesis that patients with chronic obstructive pulmonary disease experience nocturnal hypoxemia, periodic breathing and sleep disturbances when staying at moderate altitude. Sleep studies and clinical evaluations will be performed during 2 days in Zurich (490 m, low altitude baseline) and during 2 days at Davos Clavadel (1650 m), and 2 days at Davos Jakobshorn (2590 m).
Investigators
Eligibility Criteria
Inclusion Criteria
- •chronic obstructive pulmonary disease (COPD), GOLD grade 2-3
- •residents at low altitude (\<800 m)
Exclusion Criteria
- •Unstable condition, COPD exacerbation
- •Mild (GOLD 1) or very severe COPD (GOLD 4)
- •requirement for oxygen therapy at low altitude residence
- •hypoventilation
- •pulmonary hypertension
- •more than mild or unstable cardiovascular disease
- •use of drugs that affect respiratory center drive
- •internal, neurologic or psychiatric disease that interfere with protocol compliance including current heavy smoking (\>20 cigarettes per day), inability to perform 6 min walk test.
- •previous intolerance to moderate altitude (\<2600m).
- •Exposure to altitudes \>1500m for \>2 days within the last 4 weeks before the study.
Outcomes
Primary Outcomes
Change in mean nocturnal oxygen saturation from baseline measured at 490 m
Time Frame: Change in mean nocturnal oxygen saturation from 490 m baseline during 2 days at 2590 m
mean nocturnal oxygen saturation measured by pulse oximetry
Change in apnea/hypopnea index from baseline measured at 490 m
Time Frame: Change in apnea/hypopnea index from 490 m baseline during 2 days at 2590 m
apnea/hypopnea index measured by polysomnography
Secondary Outcomes
- Change in mean nocturnal oxygen saturation from baseline measured at 490 m(Change in mean nocturnal oxygen saturation from 490 m baseline during 2 days at 1650 m)
- Change in apnea/hypopnea index from baseline measured at 490 m(Change in apnea/hypopnea index from 490 m baseline during stay at 1650 m)
- Change in subjective sleep quality from baseline measured at 490 m(Change in subjective sleep quality from 490 m baseline during 2 days at 1650 m)
- Change in reaction time from baseline measured at 490 m(Change in reaction time from 490 m baseline during 2 days at 1650 m)